Tag: Herpes Zoster (Shingles)
Pain and Itch Highly Prevalent Months After Herpes Zoster
Pain linked to increased costs and has large impact on quality of life; itch has limited impact on QoL
Stellate Ganglion Block Beneficial in Postherpetic Neuralgia
Report demonstrates benefit in severe photophobia secondary to trigeminal postherpetic neuralgia
Varicella Zoster Vaccine Linked to Corneal Inflammation
Important for physicians to know when giving vaccine to individuals with history of keratitis
History of Asthma May Be Linked to Shingles Risk in Adults
Odds of herpes zoster 70 percent higher among people with respiratory condition
Risk of CV Events Up After Shingles Diagnosis in Seniors
Chance of stroke, myocardial infarction increased most in the first week after diagnosis
Herpes Zoster Risk in RA Up With Older Age, Prednisone Dose
HZ risk comparable after initiation of TNFi, non-TNFi, and conventional synthetic DMARDs
Neurotoxicity Seen With Acyclovir at Recommended Dose in Dialysis
Case report describes acyclovir-induced neurotoxicity in patient treated with recommended dose
Herpes Zoster Vaccine Not Cost-Effective in Adults Aged 50 Years
At willingness-to-pay threshold of $100,000 per QALY, 3% probability of vaccine being cost-effective
Vaccine Tied to Less Postherpetic Neuralgia in Shingles
Findings support immunization of older adults
Subunit Vaccine Efficacious Against Herpes Zoster
Vaccine efficacy 97.2 percent overall in phase 3 trial among adults aged 50 years and older
